Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Magenta Therapeutics
Cambridge, Massachusetts, United Statesmagentatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Magenta’s lead program, MGTA -117, a CD117-targeted antibody-drug conjugate for targeted conditioning prior to hematopoietic stem cell transplant or gene therapy, showed promising single-agent activity and tolerability in early clinical trials. The company also advanced MGTA -145 for improved stem cell mobilization into Phase 2 studies but did not reach commercialization before winding down operations.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugateCell therapySmall molecule
- Industry
- Biotech
02
Partnerships
bluebird bio (stem cell mobilization)Beam Therapeutics (“base editing” gene therapies with targeted conditioning)National Marrow Donor Program / Be The Match BioTherapies
Beyond the preview
Go deeper on Magenta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magenta Therapeutics.